RENE DARVEAUX: Open Payments
NPI 1205866696 · BELLAIRE, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,216 in 62 payments from 20 companies in 2025. Trend: 2023 $1,723 · 2024 $1,460 · 2025 $1,216
Food & beverage: $1,216
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 13 | $267 |
| GlaxoSmithKline, LLC. | 10 | $174 |
| Lilly USA, LLC | 4 | $115 |
| ABBVIE INC. | 5 | $100 |
| Bayer Healthcare Pharmaceuticals Inc. | 4 | $73 |
| AstraZeneca Pharmaceuticals LP | 3 | $59 |
| Paratek Pharmaceuticals, Inc. | 2 | $54 |
| Dexcom, Inc. | 2 | $50 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 3 | $48 |
| Amgen Inc. | 3 | $48 |
Products named: TRELEGY ELLIPTA, JARDIANCE, Rybelsus, Wegovy, Ozempic, Kerendia, FARXIGA, XHANCE.
Industry payments across TX — which companies pay providers there.
